Sue Mahony, PhD

Dr. Mahony has been a director since 2017.  She currently serves as president, Lilly Oncology, a senior vice president, Eli Lilly and Company, and a member of the company’s Executive Committee. Prior to that, she was senior vice president, human resources and diversity. Dr. Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in the United Kingdom and Europe in oncology/hematology and cardiovascular medicine for Schering-Plough, Amgen and Bristol-Myers Squibb with global and direct responsibility for the US, Japan, China, Europe and Canada. Since joining Lilly, Dr. Mahony has held roles in global marketing, product development, six sigma and general management, including global brand development leader for duloxetine (Cymbalta®) and fluoxetine (Prozac®), and country manager for Canada. Dr. Mahony earned both Bachelor of Science and PhD degrees in pharmacy from Aston University in the UK, which also awarded her an honorary doctorate degree. She received an MBA from the London School of Business, and in 2010, she was recognized as one of the Indianapolis Business Journal’s “Women of Influence.” Dr. Mahony is a member of the Board of Directors of the Park Tudor School in Indianapolis.

Independent Director